Molecular mechanisms of the inhibitory effects of jiangu granule‑containing serum on RANKL‑induced osteoclastogenesis

Huang,Yunmei; Lin,Yu; Wu,Yinsheng; Zeng,Jianwei; Huang,Meiya; Guo,Shiming; Luo,Wenjuan; Lin,Haiming; Lin,Yanping

doi:10.3892/mmr.2017.7645

Molecular mechanisms of the inhibitory effects of jiangu granule‑containing serum on RANKL‑induced osteoclastogenesis

Authors:
- Yunmei Huang
- Yu Lin
- Yinsheng Wu
- Jianwei Zeng
- Meiya Huang
- Shiming Guo
- Wenjuan Luo
- Haiming Lin
- Yanping Lin
View Affiliations

Affiliations: Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Minhou Shangjie, Fuzhou, Fujian 350122, P.R. China, Joint Surgery, Fuzhou No. 2 Hospital Affiliated Xiamen University, Fuzhou, Fujian 350007, P.R. China, Fujian Provincial Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Minhou Shangjie, Fuzhou, Fujian 350122, P.R. China
Published online on: September 27, 2017 https://doi.org/10.3892/mmr.2017.7645
Pages: 8420-8426

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Postmenopausal osteoporosis (PMOP) is characterized by increased bone loss due to enhanced osteoclastogenesis and bone resorption. A Chinese herbal formula, jiangugranule (JG), exhibited great efficacy in the clinical treatment of PMOP. However, the molecular mechanisms underlying the therapeutic effects remain unclear. The present study aimed to examine the effects of JG‑containing serum on receptor activator of nuclear factor‑κB (NF‑κB) ligand (RANKL)‑induced osteoclastogenesis. Osteoclast precursor RAW264.7 cells were cultured and treated with JG‑containing serum in the presence of RANKL. Following 6 days of culture, the cells were stained with tartrate‑resistant acid phosphatase and the rate of differentiation was calculated. In addition, cells were treated with JG‑containing serum for 24, 48 and 96 h and total RNA and proteins were extracted for reverse transcription‑quantitative polymerase chain reaction and western blot analysis to detect mRNA and protein expression, respectively, of key molecules in the RANK/RANKL signaling pathway, including RANK, tumor necrosis factor receptor‑associated factor 6, NF‑κB (p50 and p52 subunits), c‑Fos and nuclear factor of activated T cells, cytoplasmic 1 (NFATc1). The results revealed that JG‑containing serum inhibited RANKL‑induced osteoclastogenesis and reduced mRNA and protein expression of RANK, c‑Fos and NFATc1. The results suggested that JG may regulate osteoclast differentiation through the RANK/RANKL signaling pathway, which may be a possible mechanism for the therapeutic effects of JG on PMOP.

View Figures

View References

1	Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 94:646–650. 1993. View Article : Google Scholar : PubMed/NCBI
2	Pacifici R: Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res. 11:1043–1051. 1996. View Article : Google Scholar : PubMed/NCBI
3	Seifert-Klauss V, Fillenberg S, Schneider H, Luppa P, Mueller D and Kiechle M: Bone loss in premenopausal, perimenopausal and postmenopausal women: Results of a prospective observational study over 9 years. Climacteric. 15:433–440. 2012. View Article : Google Scholar : PubMed/NCBI
4	de Villiers TJ: Bone health and osteoporosis in postmenopausal women. Best Pract Res Clin Obstet Gynaecol. 23:73–85. 2009. View Article : Google Scholar : PubMed/NCBI
5	Tella SH and Gallagher JC: Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 142:155–170. 2014. View Article : Google Scholar : PubMed/NCBI
6	Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J and Dansey R: Bench to bedside: Elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 11:401–419. 2012. View Article : Google Scholar : PubMed/NCBI
7	Bridgeman MB and Pathak R: Denosumab for the reduction of bone loss in postmenopausal osteoporosis: A review. Clin Ther. 33:1547–1559. 2011. View Article : Google Scholar : PubMed/NCBI
8	Wang XX, Zhang YL and Huang QF: Discussion on the main pathogenesis in traditional Chinese medicine and etiology about primary osteoporosis. Zhong Xi Yi Jie He Xue Bao. 8:1119–1123. 2010.(In Chinese). View Article : Google Scholar : PubMed/NCBI
9	Li DT, Li FY, Wang J, Liu JH, Yan N, Cheng YM, Hu AH, Jiang HY, Shi FL, Zhang MZ, et al: A study of diagnostic criteria for traditional Chinese medicine syndromes in osteoporosis. Zhong Xi Yi Jie He Xue Bao. 9:1326–1332. 2011.(In Chinese). View Article : Google Scholar : PubMed/NCBI
10	Lin YP, Zhou RX and Guo SM: Effect of jiangu granule on quality of bone in model rats with osteoporosis induced by ovariectomy. Zhongguo Zhong Xi Yi Jie He Za Zhi. 24:431–434. 2004.(In Chinese). PubMed/NCBI
11	Lin YP, Ma JH and Feng EY: Study on preventive effect of jiangu granule on osteoporosis in ovariectomized rats. Zhongguo Zhong Xi Yi Jie He Za Zhi. 22:369–371. 2002.(In Chinese). PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Ju D, Liu M, Zhao H and Wang J: Mechanisms of ‘kidney governing bones’ theory in traditional Chinese medicine. Front Med. 8:389–393. 2014. View Article : Google Scholar : PubMed/NCBI
14	Li Y, Tong J, Zhou YJ and Xu XY: Research progress on anti-osteoporotic active ingredients and pharmacological action mechanism of traditional Chinese kidney-tonifying and bone-strengthening drugs. Zhongguo Zhong Yao Za Zhi. 40:1038–1043. 2015.(In Chinese). PubMed/NCBI
15	Crockett JC, Rogers MJ, Coxon FP, Hocking LJ and Helfrich MH: Bone remodelling at a glance. J Cell Sci. 124:991–998. 2011. View Article : Google Scholar : PubMed/NCBI
16	Hadjidakis DJ and Androulakis II: Bone remodeling. Ann NY Acad Sci. 1092:385–396. 2006. View Article : Google Scholar : PubMed/NCBI
17	Kartsogiannis V and Ng KW: Cell lines and primary cell cultures in the study of bone cell biology. Mol Cell Endocrinol. 228:79–102. 2004. View Article : Google Scholar : PubMed/NCBI
18	Väänänen HK, Zhao H, Mulari M and Halleen JM: The cell biology of osteoclast function. J Cell Sci. 113:377–381. 2000.PubMed/NCBI
19	Liu C, Walter TS, Huang P, Zhang S, Zhu X, Wu Y, Wedderburn LR, Tang P, Owens RJ, Stuart DI, et al: Structural and functional insights of RANKL-RANK interaction and signaling. J Immunol. 184:6910–6919. 2010. View Article : Google Scholar : PubMed/NCBI
20	Kuroda Y and Matsuo K: Molecular mechanisms of triggering, amplifying and targeting RANK signaling in osteoclasts. World J Orthop. 3:167–174. 2012. View Article : Google Scholar : PubMed/NCBI
21	Inoue Ji, Ishida T, Tsukamoto N, Kobayashi N, Naito A, Azuma S and Yamamoto T: Tumor necrosis factor receptor-associated factor (TRAF) family: Adapter proteins that mediate cytokine signaling. Exp Cell Res. 254:14–24. 2000. View Article : Google Scholar : PubMed/NCBI
22	Armstrong AP, Tometsko ME, Glaccum M, Sutherland CL, Cosman D and Dougall WC: A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem. 277:44347–44356. 2002. View Article : Google Scholar : PubMed/NCBI
23	Asagiri M and Takayanagi H: The molecular understanding of osteoclast differentiation. Bone. 40:251–264. 2007. View Article : Google Scholar : PubMed/NCBI
24	Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, Young F and Boyce BF: NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res. 17:1200–1210. 2002. View Article : Google Scholar : PubMed/NCBI
25	Soysa NS and Alles N: NF-kappaB functions in osteoclasts. Biochem Biophys Res Commun. 378:1–5. 2009. View Article : Google Scholar : PubMed/NCBI
26	Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ and Wagner EF: Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet. 24:184–187. 2000. View Article : Google Scholar : PubMed/NCBI
27	Zhao Q, Wang X, Liu Y, He A and Jia R: NFATc1: Functions in osteoclasts. Int J Biochem Cell Biol. 42:576–579. 2010. View Article : Google Scholar : PubMed/NCBI